353
Participants
Start Date
September 13, 2019
Primary Completion Date
August 31, 2022
Study Completion Date
August 31, 2022
Fremanezumab
Monthly 225 mg subcutaneous
Placebo
Matching Placebo
Teva Investigational Site 14345, The Bronx
Teva Investigational Site 14335, Brooklyn
Teva Investigational Site 63075, Athens
Teva Investigational Site 63077, Marousi
Teva Investigational Site 14338, Philadelphia
Teva Investigational Site 40055, Turku
Teva Investigational Site 30237, Milan
Teva Investigational Site 58320, Vinnytsia
Teva Investigational Site 14336, Pikesville
Teva Investigational Site 32733, Westerstede
Teva Investigational Site 30235, Pavia
Teva Investigational Site 14334, Jacksonville
Teva Investigational Site 14341, Orlando
Teva Investigational Site 14329, Hialeah
Teva Investigational Site 40056, Tampere
Teva Investigational Site 14411, Tampa
Teva Investigational Site 14339, Nashville
Teva Investigational Site 14333, Memphis
Teva Investigational Site 31276, Seville
Teva Investigational Site 35267, Saint-Priest-en-Jarez
Teva Investigational Site 32737, Essen
Teva Investigational Site 32731, Essen
Teva Investigational Site 31274, Valencia
Teva Investigational Site 31272, Valladolid
Teva Investigational Site 31273, Zaragoza
Teva Investigational Site 30236, Florence
Teva Investigational Site 14343, Bolivar
Teva Investigational Site 35265, Bron
Teva Investigational Site 40058, Kuopio
Teva Investigational Site 14330, Little Rock
Teva Investigational Site 14342, Denver
Teva Investigational Site 30242, Catanzaro
Teva Investigational Site 40057, Oulu
Teva Investigational Site 14337, San Diego
Teva Investigational Site 14340, Portland
Teva Investigational Site 50482, Moscow
Teva Investigational Site 50483, Moscow
Teva Investigational Site 50480, Moscow
Teva Investigational Site 50481, Nizhny Novgorod
Teva Investigational Site 58321, Odesa
Teva Investigational Site 80172, Hadera
Teva Investigational Site 80178, Petah Tikva
Teva Investigational Site 80173, Holon
Teva Investigational Site 80175, Rehovot
Teva Investigational Site 80177, Jerusalem
Teva Investigational Site 14332, Stamford
Teva Investigational Site 14331, Waltham
Teva Investigational Site 54190, Choceň
Teva Investigational Site 54183, Prague
Teva Investigational Site 54184, Prague
Teva Investigational Site 54185, Prague
Teva Investigational Site 54186, Rychnov nad Kněžnou
Teva Investigational Site 32736, Dresden
Teva Investigational Site 32734, Leipzig
Teva Investigational Site 32732, Mittweida
Teva Investigational Site 63076, Glyfada
Teva Investigational Site 30232, Roma
Teva Investigational Site 30234, Rome
Teva Investigational Site 53447, Krakow
Teva Investigational Site 53445, Poznan
Teva Investigational Site 53446, Warsaw
Teva Investigational Site 53448, Wroclaw
Teva Investigational Site 58319, Kiyv
Teva Investigational Site 34254, London
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY